|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
PPAR�� |
|
��� |
|
PPAR������ |
|
PPAR������ |
| ��������������� | |
|
������ |
|
��־�� |
|
������ |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
��������ø����ֳ�Ｄ�����������м��
������, ��־��, ������
�㶫ҽѧԺ����ҽԺƤ����, տ��524023
��������ø����ֳ�Ｄ�����������弤�����峬������³�Ա,���ɹ�������ø����ֳ�Ｄ����������¡���3�ֺ�������ɵġ���������ø����ֳ�Ｄ������ô�ת¼ˮƽ�ϲ��������ϸ�����ܼ���������ĵ��ع���,����֬��ϸ���ֻ����ǡ�֬��л����������Ӳ������ϸ���ķֻ��γɵȡ����������о����������п�������ֳ����,����֢�Ե�Ƥ��������м���Ĺ�ϵ���С�
[2] Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol, 2000, 136:609-616.
[3] Owen GI, Zelent A. Origins and evolutionary diversification of the nuclear receptor superfamily. Cell Mol Life Sci, 2000, 57:809-827.
[4] Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem,2001,70:341-367.
[5] Vamecq J, Latruffe N. Medical significance of peroxisome proliferatoractivated receptors. Lancet, 1999, 354:141-148.
[6] Shearer BG, Hoekstra WJ. Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem, 2003, 10:267-280.
[7] Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry,2002,41:6640-6650.
[8] Rivier M, Safonova I, Lebrun P, et al. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol, 1998, 111: 1116-1121.
[9] Westergaard M, Henningsen J, Svendsen ML,et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol, 2001, 116:702-712.
[10] Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis. Curr Drug Targets Inflamm Allergy, 2004, 3:205-211.
[11] Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma(PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem, 2000, 275:4541-4544.
[12] Sugiyama H, Nonaka T, Kishimoto T, et al. Peroxisome proliferatoractivated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol, 2000, 30:3363-3370.
[13] Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391:82-86.
[14] De Rie MA, Zonneveld IM, Witkamp L, et al. Soluble interkeukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol, 1996, 76:357-360.
[15] Travers JB, Hamid QA, Norris DA, et al. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest, 1999, 104:1181-1189.
[16] Ricote M, Li AC, Willson TM,et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.Nature, 1998, 391:79-82.
[17] Pershadsingh HA, Sproul JA, Benjamin E, et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol, 1998, 134:1304-1305.
[18] Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma:therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs, 2004, 13:215-228.
[19] Kuenzli S, Saurat JH. Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology,2003,206:252-256.
[20] Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med, 2002, 53:409-435.